Welcome to our dedicated page for ASSEMBLY BIOSCIENCES SEC filings (Ticker: ASMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assembly Biosciences, Inc. filings document a clinical-stage antiviral developer with common stock listed on the Nasdaq Global Select Market under ASMB. Recent 8-K reports furnish operating results and pipeline updates tied to investigational programs for recurrent genital herpes, chronic hepatitis delta virus and chronic hepatitis B virus, including disclosures on ABI-5366, ABI-1179, ABI-6250 and ABI-4334.
The filing record also covers the company’s collaboration revenue with Gilead, material definitive agreements, registered equity and warrant offerings, and securities registered under Section 12(b). Proxy and compensation-related filings describe governance, executive compensation, equity awards and performance-based cash bonus arrangements.
ASSEMBLY BIOSCIENCES, INC. director Susan Mahony received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036.
The options vest, assuming continuous service, upon the earlier of June 4, 2027 or the date of the company’s 2027 annual meeting of stockholders. Following this grant, Mahony holds 8,000 stock options directly.
Assembly Biosciences director Lisa Johnson-Pratt received a grant of stock options for 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting. Following this grant, she holds 8,000 stock options directly.
ASSEMBLY BIOSCIENCES, INC. director Michael Houghton received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Houghton holds 8,000 stock options directly.
ASSEMBLY BIOSCIENCES, INC. director Gina Consylman received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and represent compensation rather than an open-market purchase.
The options vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Consylman holds 8,000 stock options directly, with an expiration date in 2036.
Assembly Biosciences, Inc. reported that director Anthony E. Altig received a grant of stock options to acquire 8,000 shares of Common Stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036.
These options vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Altig holds stock options for 8,000 underlying shares directly.
Assembly Biosciences, Inc. reported that its Principal Financial Officer and Principal Accounting Officer, Jeanette M. Bjorkquist, acquired 3,500 shares of common stock at no cost through a grant of restricted stock units. These RSUs represent 35% of her annual equity grant and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan that increased the shares authorized under the plan. The RSUs vest in four approximately equal installments on March 29 of each year from 2027 through 2030, assuming she remains in continuous service. Following this grant, Bjorkquist directly holds 14,589 shares of common stock.
Assembly Biosciences Chief Scientific Officer awarded RSUs. Chief Scientific Officer William E. Delaney IV received a grant of 14,000 restricted stock units of common stock at no cash cost, representing 35% of his annual equity grant. The award was contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan and became issuable after that approval on June 4, 2026. The RSUs vest in four approximately equal annual installments on March 29, 2027, 2028, 2029, and 2030, assuming continued service. Following this award, he directly holds 60,330 shares of common stock, including 688 shares acquired through the employee stock purchase plan.
ASSEMBLY BIOSCIENCES, INC. CEO and President Jason A. Okazaki received a grant of 50,750 shares of common stock in the form of restricted stock units at no cash cost. These RSUs were approved on March 29, 2026 and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.
The RSUs vest in four approximately equal annual installments on March 29, 2027, 2028, 2029, and 2030, subject to continued service. After this award, Okazaki directly holds 163,354 shares of common stock, including 688 shares acquired through the company’s Employee Stock Purchase Plan on May 14, 2026.
Assembly Biosciences, Inc. reported the results of its annual stockholder meeting held on June 4, 2026. Stockholders approved amendments to the company’s equity incentive and employee stock purchase plans, elected the full slate of director nominees, and ratified the independent auditor.
The amendment to the 2018 Stock Incentive Plan increases shares reserved for issuance from 1,478,333 to 2,678,333. The Employee Stock Purchase Plan reserve was increased from 225,000 to 515,000 shares. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Gilead Sciences, Inc., a ten percent owner of Assembly Biosciences, Inc., reported receiving a grant or other acquisition of 471,698 shares of Common Stock on May 26, 2026 at $26.50 per share. After this award, Gilead directly holds 4,977,089 Assembly common shares.